No Data
No Data
Buy Rating Affirmed for 2seventy Bio on Strong Growth Prospects and Financial Stability
2seventy bio | 10-Q: Quarterly report
2seventy Bio Is Maintained at Buy by Canaccord Genuity
2seventy Bio Is Maintained at Buy by Canaccord Genuity
Canadian Investment Banking Group: Maintaining the 2seventy bio (TSVT.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $11.00.
Canadian Investment Banking Group: Maintaining the 2seventy bio (TSVT.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $11.00.
Canaccord Genuity Maintains Buy on 2seventy Bio, Lowers Price Target to $11
Canaccord Genuity analyst John Newman maintains 2seventy bio (NASDAQ:TSVT) with a Buy and lowers the price target from $12 to $11.
2seventy Bio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 148.31% Canaccord Genuity $12 → $11 Maintains Buy 04/08/2024 170.88% Citigroup $9 → $12 Maintai